Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
CSE: ALEN.U — AI Meets Digital Health (click to learn more) What’s Behind Cannabis Stock HERB? (click to learn more) Eshbal Acquires a 55% Interest in Dare to Be Different Foods (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Gyre Therapeutics Inc GYRE

Healthcare Biotechnology
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in... see more

Current News (NDAQ:GYRE)

Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

GlobeNewswire January 5, 2026

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

GlobeNewswire November 7, 2025

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

GlobeNewswire October 15, 2025

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD-The Liver Meeting® 2025

GlobeNewswire October 14, 2025

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 5, 2025

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

GlobeNewswire August 22, 2025

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

GlobeNewswire August 11, 2025

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

GlobeNewswire June 10, 2025

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire May 29, 2025
View More News ››

Opinion & Analysis (NDAQ:GYRE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GYRE)

Gyre Therapeutics (GYRE): A Diversified Pipeline Tackling Ch

Solid play here. GYRE looking interesting with their anti-fibrotic pipeline and strong China market presence. F351 Phase 3 trial for...
MikeTester - January 23, 2025
View more Bullboard ››

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp.

Cielo Waste Solutions Corp. operates as a waste to fuels company, focuses on wood waste byproducts conversion to renewable ...
View More »

Podcasts